Quick navigation menu :

  1. Go to the content
  2. Go to main section's menu
  3. Go to Search tool
  4. Go to Help menu
  5. Go to modules
  6. Go to the list of keyboard shortcuts

Help menu :

  1. Sanofi Worldwide |
     
  2. Our Websites |
     
  3. Global Business Websites |
     
  4. Contact us |
  5. Sitemap |
  6. Help
  1. Font size

    Reduce the font size Increase the font size  
 
 

Innovation

Contact Us

Sanofi

Sanofi House,
CTS No.117-B, L&T Business Park,
Saki Vihar Road, Powai,
Mumbai 400072

Tel no. (022) 28032000
Fax no.(022) 28032846

Content :

Global Research & Development

Our R&D strategy is focused on key innovations and technologies, enabling Sanofi to respond to patients’ unmet medical needs.

 

Sanofi also explores new research paths, such as biotechnologies, nanotechnologies or biomarkers, through partnerships with other specialized companies. The aim is to develop new products in our key therapeutic areas: cardiovascular disease, thrombosis, diabetes, oncology, central nervous system disorders, internal medicine and vaccines. This allows us to identify projects that may lead to the discovery of new medications.

By taking a holistic approach to patient care, Sanofi should be able to extend its product range to treat all the stages of a disease, from prevention to the various levels of treatment. This would also support pharmacological approaches by providing services and technologies that boost the efficacy of patient treatment, monitoring and quality of life. The aim is also to develop products that are tailored to the specific needs of patients in different parts of the world.

After a complete review in of our R&D portfolio in early 2009, Sanofi now has 52 projects in clinical development, of which 14% are biotechnology products and 35% vaccines.

Pipeline

After a complete review in of our R&D portfolio in early 2009, Sanofi has 51 projects in clinical development, of which 14% are biotechnology products and 35% vaccines.

Partnerships

Sanofi is developing a partnership strategy, particularly in biotechnologies and biotherapy, forging strategic partnerships around the world with recognized experts to achieve faster, better progress towards new therapeutic solutions.

Biotechnology

Sanofi has the ambition of becoming a major player in this field and intends to raise the share of biotechnology-sourced products in its development portfolio from 14% in 2008 to 25% by 2012.

Animal experimentation

Animal experimentation is necessary for medical progress. All progress in the medical field has relied upon and will continue to rely upon the results obtained from studies involving animal experimentation at one stage or another.

Module :

Corporate information

Corporate information